Loading
Radiotherapy procedure / Breast Cancer · Interventional Study
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a recruiting interventional study registered to evaluate the safety and dosimetric characteristics of a fully automated "all-in-one" radiotherapy workflow in breast cancer patients. No results are yet reported in this registry record; the study aims to establish a standardized clinical protocol and track acute adverse events over 6 months of follow-up.
Interventional, Non Randomized, Sequential, Open label, Other purpose. Breast Cancer; age from 18 Years. Intervention: ARM1: AI-empowered AIO WBI; ARM2: Expanded-Scenario AIO RT. n = 225. 1 site: China.
This is a recruiting interventional study registered to evaluate the safety and dosimetric characteristics of a fully automated "all-in-one" radiotherapy workflow in breast cancer patients. No results are yet reported in this registry record; the study aims to establish a standardized clinical protocol and track acute adverse events over 6 months of follow-up.
Follow-up duration is 6 months for acute adverse events; long-term outcomes not mentioned in this record.
Once results are available, this study may establish safety and feasibility of an automated, one-stop radiotherapy workflow that could reduce treatment time and improve operational efficiency. Clinicians should await final publication of adverse event and dosimetric data before considering adoption.
This is a recruiting registry record with no reported results; it describes a planned interventional study of a novel radiotherapy workflow in breast cancer, designed to establish feasibility and safety metrics.
As stated by the source record.
Quoted from the source exactly as published.
Once results are available, this study may establish safety and feasibility of an automated, one-stop radiotherapy workflow that could reduce treatment time and improve operational efficiency. Clinicians should await final publication of adverse event and dosimetric data before considering adoption.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07776301). This is a study registration, not published results. Lead sponsor: Fudan University. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 225 participants (ESTIMATED). Conditions: Breast Cancer. Interventions: OTHER: Radiotherapy procedure. Primary outcome measures: Acute adverse events , 6 months. Brief summary: This study aims to evaluate and report the clinical adverse events and dosimetric parameters in breast cancer patients undergoing an "all-in-one (AIO)" one-stop, fully automated radiotherapy workflow. By systematically tracking these clinical and physical metrics, we seek to establish a standardized clinical protocol for AIO radiotherapy in breast cancer management.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.